{"schema_version":"1.0","type":"article","title":"Adding an ADC to Lung Cancer Immunotherapy: More Tumor Responses, but Why Did Phase 3 Fall Short?","url":"https://drugnews.com.tw/articles/2026-10-01-trodelvy-evoke03-east-asia-subgroup-phase3-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-10-01-trodelvy-evoke03-east-asia-subgroup-phase3-en.md","lang":"en","date":"2026-10-01","publish_at":"2026-10-01T08:00:00+08:00","updated_at":"2026-10-01","category":"醫學大會","topic":"醫學大會","tags":["Trodelvy","EVOKE-03","肺癌","TROP2 ADC","東亞次群","浩鼎"],"summary":"Adding an ADC increased response rates but missed the prespecified PFS threshold and increased toxicity in EVOKE-03. What evidence would justify further development, and what must regional hypotheses and distinct TROP2 products demonstrate?","key_points":[],"facts":[],"sections":["【01｜The Additional Drug Must Beat an Active Comparator】","【02｜An Additional 4.1 Months Still Needs Interpretation】","【03｜Additional Burden Does Not Disappear Because the Toxicity Is Familiar】","【04｜What Next Step Would the East Asian Signal Justify?】","【05｜For OBI, Sharing TROP2 Still Requires an Answer of Its Own】"],"references":[],"images":[{"alt":"About 620 patients with untreated metastatic NSCLC, high PD-L1 expression and specified sensitizing EGFR, ALK or ROS1 alterations excluded are divided into SG plus pembrolizumab and pembrolizumab-alone arms, both leading to PFS and OS primary endpoints.","url":"https://drugnews.com.tw/assets/articles/trodelvy-evoke03-east-asia-subgroup-phase3-en/FIG01_EN_v2.png"},{"alt":"The figure uses four parallel areas with the consistent arm order “SG + pembrolizumab / Pembrolizumab”: PFS shows 11.8 / 7.7 months, HR 0.81 and P=0.0252 with the prespecified threshold not met; interim OS shows 21.5 / 22.8 months; ORR shows 55.6% / 43.7%; and Grade ≥3 TRAEs show 55.7% / 16.5%. No Kaplan-Meier survival curve is shown, and neither ORR nor HR is presented as a successful primary PFS result.","url":"https://drugnews.com.tw/assets/articles/trodelvy-evoke03-east-asia-subgroup-phase3-en/FIG02_EN_v1.png"},{"alt":"The left side shows the overall 620-patient primary analysis with the PFS threshold not met. On the right, a larger East Asia area fully contains a smaller China-only area. The image itself shows only “Favorable PFS trend” for East Asia and “OS: post-hoc exploration” for China-only, with no forest plot, regional n, confidence intervals or interaction statistics; area size does not represent sample proportion or effect magnitude. The accompanying caption adds that OS in both the East Asian and China-only patient strata was described as post-hoc exploratory, while prespecification of the East Asia PFS subgroup remains unknown.","url":"https://drugnews.com.tw/assets/articles/trodelvy-evoke03-east-asia-subgroup-phase3-en/FIG03_EN_v1.png"},{"alt":"A central TROP2-positive tumor cell with membrane markers connects to three distinct abstract ADCs: Trodelvy, OBI-992 and OBI-902. Each needs its own human evidence; no cross-trial ranking or adjacent supply-chain companies are shown.","url":"https://drugnews.com.tw/assets/articles/trodelvy-evoke03-east-asia-subgroup-phase3-en/FIG04_EN_v3_20260927.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/trodelvy-evoke03-east-asia-subgroup-phase3-en/FIG01_EN_v2.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-10-01）。Adding an ADC to Lung Cancer Immunotherapy: More Tumor Responses, but Why Did Phase 3 Fall Short?。https://drugnews.com.tw/articles/2026-10-01-trodelvy-evoke03-east-asia-subgroup-phase3-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-10-01-trodelvy-evoke03-east-asia-subgroup-phase3.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}